Harvard Business Review

OCTOBER 26, 2011

Between 2006 and 2008, more than $1 billion venture-capital dollars were channeled into startups focused on solar, wind and biofuel technologies. In the last year, however, early-stage investments in clean energy production technologies have fallen substantially (see the table at the end of this piece for more detail).

Energy 13

Energy Finance IPO Biotechnology 13

Harvard Business Review

MAY 20, 2014

In pharmaceuticals, the largest company, Pfizer, is the result of decades of mergers. The current corporate entity is comprised of firms that used to be called: King Pharmaceuticals, Wyeth, American Cyanamid, Lederle, Pharmacia, Upjohn, Searle, SUGEN, Warner-Lambert, Parke-Davis and others. Economy Entrepreneurship Finance'

Pharmaceuticals 11

Pharmaceuticals Banking Chemicals Entrepreneur 11

Harvard Business Review

SEPTEMBER 4, 2015

We’ve found that CEOs of big pharmaceutical companies, for example, are more likely to have a background as company lawyers, salespeople, or finance managers, than one in medicine or pharmaceutical R&D. Pharmaceuticals. The data captured a 20-year period, from 1995 to 2014. Overall, it is a messy picture.

CEO 8

CEO Innovation Pharmaceuticals Merchandising 8

Harvard Business Review

APRIL 2, 2018

We invest billions of dollars each year in medicines, new technologies, doctors, and hospitals—all with the goal of improving health, arguably our most prized commodity. So reducing investments in low-value care services means spending less on doctors, hospitals, and other health care technologies. rawpixel/Getty Images.

Health Care 8

Health Care Insurance Pharmaceuticals Incentives 8

Harvard Business Review

APRIL 16, 2012

This raises the question of whether retaining strategic cash makes economic sense and should be viewed as a legitimate corporate finance tool in today's environment. Strategic cash also can be used to finance long-term reinvestment programs in the business—which is especially valuable to companies in capital-intensive industries (e.g.,

Company 15

Company Cost of Capital Finance Long-term 15

Harvard Business Review

OCTOBER 24, 2014

In addressing the billion-dollar adherence problem, Vitality (since acquired by NANTHEALTH ) considered the interests of the players in the diverse ecosystem, including pharmaceutical companies, retail pharmacies, and health care providers. Information & technology Operations Organizational culture Product development'

Productivity 8

Productivity Products Company Engineering 8

Harvard Business Review

AUGUST 3, 2012

They might make a targeted acquisition here or there, form an alliance now and again, or license in some specialized technology, but by and large they made their own drugs, supporting big, fully staffed research labs, which they would then market themselves. Historically, big pharma firms made their own drugs.

Licensing 14

Licensing Depreciation Pharmaceuticals Budgeting 14

Harvard Business Review

JULY 4, 2017

’ One could imagine an Apple car that is a Tesla-like product—one with comparable speed, self-driving technology, aesthetics, and features–but is so seamlessly integrated with the Apple ecosystem and requires a new sized iPhone, or some kind of blend of iPhone, iPad or MacBook. How about a man cave on wheels? Or a kitchen?

Transportation 10

Transportation Sports Pharmaceuticals Health Care 10

Harvard Business Review

APRIL 19, 2016

Carmakers have started using 3D technology to produce parts. Imagine the changes afoot in the pharmaceutical, medical device, automotive, and consumer electronics industries. The technology is expected to lead to reductions in the cost of employment, capital investment, shipping and inventory as well.

Supply Chain 8

Supply Chain Execution Analysis Technology 8

Harvard Business Review

NOVEMBER 9, 2011

COOs are relatively common in service industries such as financial services, energy, information technology and telecommunications, but in manufacturing sectors — such as automotive, chemical, and pharmaceutical companies — they are relatively rare.

COO 14

COO Sample Telecommunications Automotive 14

Harvard Business Review

MAY 26, 2014

But ongoing changes in policy, technology, and industry culture are now creating unprecedented opportunities for those with just the right kind of crazy. Top-tier thinkers from data science, business, finance, and the digital world are coming together to find new solutions. Consumer technology offers direct access to patients.

Health Care 8

Health Care Venture Funding Entrepreneur Pharmaceuticals 8

Harvard Business Review

AUGUST 29, 2011

"There's a sense that a woman is just working until she gets married, [that] she is not a long-term resource," said one senior finance professional. Women are critical contributors in finance, info-tech, pharmaceutical research, and other industries that are driving the growth of India Inc. We do all of them.".

Stress 16

Stress Human Resources Pharmaceuticals Finance 16

Harvard Business Review

OCTOBER 20, 2016

Meanwhile the Institute of International Finance forecasted net capital flows for emerging markets in 2015 would be negative for the first time since 1988. pharmaceutical company, had to abandon its $106 billion attempt to buy British drug maker AstraZeneca in the face of opposition from UK politicians. This year, for example, the U.S.

Globalization 8

Globalization Banking Policies Politics 8

Harvard Business Review

NOVEMBER 20, 2015

One result is that they keep their cards close to their chests about what they are looking for (at first), while expecting you to reveal everything – your finances, pricing, ownership, human resources, production processes, quality assurance, customer service procedures, KPIs, and existing customers.

Supply Chain 8

Supply Chain Collins Golden Handcuff Pharmaceuticals 8

Harvard Business Review

AUGUST 23, 2012

For highly regulated sectors like finance, social media can be a legal minefield. These hurdles aren't unique to financial services — insurance, pharmaceuticals, health care and government all face regulation, to name a few examples. without any compliance process or technology in place.". The risks and penalties are real.

Compliance 15

Compliance Media Compliance Officer Policies 15

Harvard Business Review

FEBRUARY 23, 2011

The first part of the conference's message, that the infrastructure of the continent is greatly wanting, was a topic of many panels, including a pair of engaging ones on technology, but it was brought home most vividly in another context, by Thierry Tanoh , a vice president at the International Finance Corp.

Conference 14

Conference Pharmaceuticals Politics Entrepreneur 14

Harvard Business Review

AUGUST 2, 2011

In reality, each country needs the other to succeed in order to thrive — to finance growth, secure export markets, train talent, transfer technology, and more. For example, pharmaceutical firms license compounds to each other and co-promote products in different markets.

Apparel 15

Apparel Pharmaceuticals Finance Licensing 15

Harvard Business Review

SEPTEMBER 5, 2016

Cigna is the first insurance company to get pharmaceutical companies to agree to value pricing based on results for certain cholesterol-lowering drugs. Finally, some companies have struggled to finance their activities without payment while they work on delivering the results, limiting their ability to innovate too.

Incentives 8

Incentives Health Care Education Insurance 8

Harvard Business Review

SEPTEMBER 10, 2013

Corporate R&D too often focuses on refining technologies that are already in use. In the 1990s and 2000s, for example, several corporate-venture initiatives helped pharmaceutical companies catch up with rapid advances in bioscience that were threatening to undermine the value of their well-established expertise. Finance Innovation'

Venture Capitalist 8

Venture Capitalist Venture Funding Innovation Incentives 8

Harvard Business Review

SEPTEMBER 10, 2013

Corporate R&D too often focuses on refining technologies that are already in use. In the 1990s and 2000s, for example, several corporate-venture initiatives helped pharmaceutical companies catch up with rapid advances in bioscience that were threatening to undermine the value of their well-established expertise. Ready to Innovate?

Venture Capitalist 8

Venture Capitalist Venture Funding Innovation Incentives 8

Harvard Business Review

JUNE 8, 2015

Pharmaceutical companies, buffeted by regulatory changes, new drug technologies that alter entry barriers and competition, price pressures, and an estimated 300,000 job cuts since 2000, seem to fit the popular narrative of large organizations unable to deal with disruptive forces. It’s not just products.

Health Care 8

Health Care Venture Capitalist Strategic Fit Pharmaceuticals 8

Harvard Business Review

MAY 1, 2013

Without adequate financing, ministries of health and even private hospitals in developing countries often don''t have the resources needed to purchase diagnostic equipment, train workers, and ensure access to appropriate treatment. Three people die every minute from tuberculosis — a treatable and largely preventable disease.

Health Care 8

Health Care ROI NGO Long-term 8

Harvard Business Review

SEPTEMBER 13, 2011

Here are some common examples: When pharmaceutical companies announce that a new drug has been "approved," they are actually saying that their researchers made some breakthrough discoveries as far back as fifteen years ago. In other words, changes in sales results may not be a sufficient measure of current performance.

Short-term 15

Short-term Pharmaceuticals Long-term Maturity 15

Harvard Business Review

JANUARY 26, 2011

Companies included in the ETF include major airlines, pharmaceuticals, industrials, and technology. By the end of October in 2010, the market value of the 100 constituent stocks reached 582 billion RMB, accounting for 31% of the total market value of the Shanghai Stock Exchange's A shares.

Long-term 15

Long-term Sample Report Pharmaceuticals 15

Harvard Business Review

MARCH 24, 2011

Among McKinsey's biggest clients in the 1990s were pharmaceuticals and financial-services companies. The strategy firms saw some of their best talent head off to startups, which promised untold riches, at least until the Dotbust of 2000, and to Wall Street or Greenwich or wherever the racier genii of modern finance ply their trade.

McKinsey 15

McKinsey Consultative Waterman Intellectual Capital 15

Harvard Business Review

MAY 5, 2016

sanctions are delaying these projects being financed. more competition to reduce consumer prices, sharing international best practices, technology transfer, public-private partnerships) needed to boost the economy’s health. However, remaining U.S. financial system for bank transactions related to Iran.

Tourism 8

Tourism Banking Due Diligence Hotels 8

Harvard Business Review

FEBRUARY 4, 2013

Perhaps surprisingly, two leading examples come from pharmaceutical companies. We're moving towards innovation in technology, pricing, business models and partnerships," explains head of corporate responsibility management, Dorje Mundle, of the company's base-of-the-pyramid operations. Breakthrough Finance.

EPS 8

EPS Innovation CEO Pharmaceuticals 8

Harvard Business Review

FEBRUARY 20, 2014

You can read about it in recent issues of The Economist , The New York Times , and in the book The Second Machine Age by Erik Brynjolfsson and Andrew McAfee of the Massachusetts Institute of Technology. The arguments are familiar. Today, there are 116 million people employed in the service sector, according to the Bureau of Labor Statistics.

Intellectual Capital 8

Intellectual Capital Magazine Creativity Pharmaceuticals 8

Marshall Goldsmith

FEBRUARY 8, 2018

Authority on new technology and communication. Darek Lenart – Senior VP HR, Finance MasterCard. Former HR director with Pepsi Central Eastern Europe, and gained HR expertise at PLIVA Pharmaceutical Company (now part of Teva Group). Claire Diaz-Ortiz – Technology innovator and speaker. While at Arthur J. Entrepreneurs.

Executive Coaching 70

Executive Coaching CEO Banking Magazine 70

Harvard Business Review

DECEMBER 12, 2018

A new generation of philanthropists, whose wealth was created via entrepreneurship in technology-driven fields, has the unique opportunity to make a real difference in speeding the pace of progress in the fight against cancer. Andrew Lo, a finance professor at MIT, has been a trailblazer in this area. Luxy Images/Getty Images.

Pharmaceuticals 8

Pharmaceuticals Venture Funding Finance Development 8

Mills Scofield

NOVEMBER 11, 2014

This is taken from The Intercollegiate Finance Journal (IFJ) is an undergraduate student-run journal about how current finance, economics, business and technology issues affect students'' lives. Please consider supporting the IFJ to ensure that our youth''s voices are heard and heeded. ~~~~~~~~~~~~~~~~~~~~~~~~~~~.

Finance 131

Finance Incentives Education Pharmaceuticals 131

Harvard Business Review

AUGUST 23, 2016

Both Republicans and Democrats say the most effective board committee is audit/finance. Meanwhile, Democrats place greater importance on technology expertise and risk management. pharmaceuticals, biotechnology & life sciences, health care equipment and services); Industrials (e.g.,

Politics 8

Politics Committee Telecommunications Diversity 8